Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C35H37N3O2 |
Molecular Weight | 531.6872 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=NC2=C(C3=C(C=CC=C3)N2CC4=CC=CC(=C4)[C@H](C5CCCC5)C(=O)N[C@@H](CO)C6=CC=CC=C6)C(C)=C1
InChI
InChIKey=AMNXBQPRODZJQR-DITALETJSA-N
InChI=1S/C35H37N3O2/c1-23-19-24(2)36-34-32(23)29-17-8-9-18-31(29)38(34)21-25-11-10-16-28(20-25)33(27-14-6-7-15-27)35(40)37-30(22-39)26-12-4-3-5-13-26/h3-5,8-13,16-20,27,30,33,39H,6-7,14-15,21-22H2,1-2H3,(H,37,40)/t30-,33-/m0/s1
Molecular Formula | C35H37N3O2 |
Molecular Weight | 531.6872 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Implitapide is a microsomal triglyceride transfer protein (MTP) inhibitor with antihyperlipidemic activity. Microsomal triglyceride transfer protein (MTP) is essential for the synthesis of both chylomicron in the intestine and very low-density lipoprotein in the liver. In an animal model, inhibition of MTP by implitapide reduced both total cholesterol and triglyceride levels and suppressed progression of atherosclerotic lesions in apolipoprotein E knockout mice fed a Western-type diet.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15684478
mice: 3.2 mg/kg/day
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 16:39:18 GMT 2023
by
admin
on
Sat Dec 16 16:39:18 GMT 2023
|
Record UNII |
Q70OH404HR
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
188904
Created by
admin on Sat Dec 16 16:39:19 GMT 2023 , Edited by admin on Sat Dec 16 16:39:19 GMT 2023
|
||
|
FDA ORPHAN DRUG |
188704
Created by
admin on Sat Dec 16 16:39:19 GMT 2023 , Edited by admin on Sat Dec 16 16:39:19 GMT 2023
|
||
|
NCI_THESAURUS |
C29703
Created by
admin on Sat Dec 16 16:39:19 GMT 2023 , Edited by admin on Sat Dec 16 16:39:19 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
177469-96-4
Created by
admin on Sat Dec 16 16:39:18 GMT 2023 , Edited by admin on Sat Dec 16 16:39:18 GMT 2023
|
PRIMARY | |||
|
5745206
Created by
admin on Sat Dec 16 16:39:19 GMT 2023 , Edited by admin on Sat Dec 16 16:39:19 GMT 2023
|
PRIMARY | |||
|
CHEMBL2105804
Created by
admin on Sat Dec 16 16:39:19 GMT 2023 , Edited by admin on Sat Dec 16 16:39:19 GMT 2023
|
PRIMARY | |||
|
7919
Created by
admin on Sat Dec 16 16:39:19 GMT 2023 , Edited by admin on Sat Dec 16 16:39:19 GMT 2023
|
PRIMARY | |||
|
Q70OH404HR
Created by
admin on Sat Dec 16 16:39:19 GMT 2023 , Edited by admin on Sat Dec 16 16:39:19 GMT 2023
|
PRIMARY | |||
|
C443181
Created by
admin on Sat Dec 16 16:39:19 GMT 2023 , Edited by admin on Sat Dec 16 16:39:19 GMT 2023
|
PRIMARY | |||
|
C65901
Created by
admin on Sat Dec 16 16:39:19 GMT 2023 , Edited by admin on Sat Dec 16 16:39:19 GMT 2023
|
PRIMARY | |||
|
DB04852
Created by
admin on Sat Dec 16 16:39:19 GMT 2023 , Edited by admin on Sat Dec 16 16:39:19 GMT 2023
|
PRIMARY | |||
|
DTXSID70870136
Created by
admin on Sat Dec 16 16:39:19 GMT 2023 , Edited by admin on Sat Dec 16 16:39:19 GMT 2023
|
PRIMARY | |||
|
300000019131
Created by
admin on Sat Dec 16 16:39:19 GMT 2023 , Edited by admin on Sat Dec 16 16:39:19 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|